Loading...
Sinopharm Group Co. Ltd.
1099.HK•HKSE
Healthcare
Medical - Distribution
HK$18.50
HK$-0.14(-0.75%)
Sinopharm Group Co. Ltd. (1099.HK) Financial Performance & Statements
Review Sinopharm Group Co. Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-2.02%
↓ 2.02%
Operating Income Growth
-19.90%
↓ 19.90%
Net Income Growth
-22.14%
↓ 22.14%
Operating Cash Flow Growth
-32.77%
↓ 32.77%
Operating Margin
2.77%
↑ 2.77%
Gross Margin
7.57%
↑ 7.57%
Net Profit Margin
1.21%
↑ 1.21%
ROE
9.13%
↑ 9.13%
ROIC
11.36%
↑ 11.36%
Sinopharm Group Co. Ltd. (1099.HK) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Sinopharm Group Co. Ltd. stock.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $289.78B | $294.73B | $295.62B | $144.97B |
| Cost of Revenue | $267.47B | $272.78B | $270.38B | $0.00 |
| Gross Profit | $22.31B | $21.94B | $25.24B | $144.97B |
| Gross Profit Ratio | $0.08 | $0.07 | $0.09 | $1.00 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $13.19B | $13.72B | $13.09B | $5.73B |
| Operating Expenses | $14.35B | $13.72B | $13.74B | $417.63B |
| Total Costs & Expenses | $281.81B | $286.51B | $284.12B | $139.95B |
| Interest Income | $0.00 | $0.00 | $857.59M | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $366.99M |
| Depreciation & Amortization | $1.21B | $1.15B | $1.01B | $844.04M |
| EBITDA | $10.65B | $9.53B | $13.50B | $4.31B |
| EBITDA Ratio | $0.04 | $0.03 | $0.05 | $0.03 |
| Operating Income | $7.97B | $8.22B | $12.49B | $3.46B |
| Operating Income Ratio | $0.03 | $0.03 | $0.04 | $0.02 |
| Other Income/Expenses (Net) | -$1.56B | -$625.14M | -$1.84B | $695.88M |
| Income Before Tax | $6.40B | $7.60B | $10.65B | $4.16B |
| Income Before Tax Ratio | $0.02 | $0.03 | $0.04 | $0.03 |
| Income Tax Expense | $1.88B | $1.70B | $2.53B | $987.09M |
| Net Income | $3.35B | $3.70B | $4.95B | $1.99B |
| Net Income Ratio | $0.01 | $0.01 | $0.02 | $0.01 |
| EPS | $1.07 | $1.19 | $1.59 | $0.00 |
| Diluted EPS | $1.07 | $1.19 | $1.59 | $0.00 |
| Weighted Avg Shares Outstanding | $3.11B | $3.12B | $3.12B | $0.00 |
| Weighted Avg Shares Outstanding (Diluted) | $3.11B | $3.12B | $3.12B | $0.00 |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan